MiR‐210 inhibits the expression of HOXA9 to activate the NF‐κB signaling, induces EMT, and reduces the sensitivity of pancreatic cancer cells to gemcitabine induced by HIF1A under hypoxia.23 Here, HOXA9 is linked to pancreatic neoplasm.